According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for all hemophilia A and B medications shows that 99% of Medicare beneficiaries are not covered for at least one of the drugs.
Trends: Starting Jan. 1, Express Scripts Holding Co. will exclude Factor VIII recombinant products for hemophilia treatment in its 2019 National Preferred Formulary.